– USA, MA – C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, announced the appointment of Steve Hoerter to its Board of Directors.
About Steve Hoerter
Steve Hoerter has over three decades of executive management, commercial, and board experience, most recently serving as the president and CEO of Deciphera Pharmaceuticals, which was acquired by ONO Pharmaceutical for $2.4 billion in June 2024. He transformed Deciphera from a clinical-stage company into a fully integrated global organization with the successful approval and launch of QINLOCK® for the treatment of advanced gastrointestinal stromal tumors in the U.S. and Europe, while advancing the company’s pipeline of novel product candidates. Before Deciphera, he was CCO of Agios Pharmaceuticals, where he was responsible for building the company’s commercial organization to enable the launches of its first two approved products in the U.S., TIBSOVO®, and IDHIFA®, both for the treatment of acute myeloid leukemia. Earlier in his career, he served as CCO of Clovis Oncology and held general management and commercial roles at Roche, Genentech, Chiron Corporation (acquired by Novartis), and Eli Lilly and Company. Mr. Hoerter is on the Board of Directors of ORIC Pharmaceuticals, a clinical-stage oncology company, and has previously served on the Boards of Constellation Pharmaceuticals (acquired by MorphoSys), Deciphera Pharmaceuticals, and Ignyta (acquired by Roche).
Steve Hoerter earned his B.A. from Bucknell University, his M.B.A. from Tilburg University in the Netherlands, and an M.S. in management from the Krannert School of Management at Purdue University.
About C4 Therapeutics
C4 Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes.
For more information: https://c4therapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.